TIDMMXC

RNS Number : 0972L

MGC Pharmaceuticals Limited

01 September 2023

 
 1 September   Change of registry address notification 
     2023 
  ASX Code: 
     MXC 
  LSE Code: 
     MXC

MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) provides the following update with regard to the Company's share registry address.

In accordance with ASX Listing Rule 3.15.1 and with effect from commencement of business on Monday, 18 September 2023, the Perth office of Computershare Investor Services Pty Limited is moving to:

Level 17

221 St Georges Terrace

Perth WA 6000

Telephone numbers and postal address remain unchanged.

Lodgement of documentation by member organisations, securityholders and other parties must be made at the new address from Monday, 18 September 2023.

-Ends-

Authorised for release by the Managing Director, for further information please contact:

 
 MGC Pharmaceuticals Ltd           MGC Pharmaceuticals Ltd 
  Roby Zomer                        Rowan Harland 
  CEO & Managing Director           Company Secretary 
  +61 8 6555 2950                   +61 8 6555 2950 
  info@mgcpharma.co.uk              info@mgcpharma.co.uk 
 UK IR/PR Advisers                 UK Brokers 
  IFC Advisory                      Oberon Capital 
  Graham Herring / Tim Metcalfe     Aimee McCusker / Adam Pollock 
  / Zach Cohen                      +44 203 179 5300 
  +44 203 934 6630                  aimeemccusker@oberoninvestments.com 
  mgcpharma@investor-focus.co.uk    adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CROEAKNFEAPDEEA

(END) Dow Jones Newswires

September 01, 2023 02:30 ET (06:30 GMT)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more Mgc Pharmaceuticals Charts.
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more Mgc Pharmaceuticals Charts.